Acupuncture in Patients with a Vertebral Compression Fracture: A Protocol for a Randomized, Controlled, Pilot Clinical Trial

Hyun-jong Lee¹#, Jung-chul Seo²#, Sung-hoon Park², Min-ah Kwak³, Im hee Shin⁴, Bo-mi Min⁵, Min-su Cho⁵, Woon-seok Roh⁵, Jin-yong Jung⁵*

¹ Department of Acupuncture & Moxibustion, College of Oriental Medicine, Daegu Haany University, Daegu, Korea
² Comprehensive and Integrative Medicine Institute, Daegu, Korea
³ Department of Internal Medicine, College of Oriental Medicine, Daegu Haany University, Daegu, Korea
⁴ Department of Medical Statistics, School of Medicine, Catholic University, Daegu, Korea
⁵ Department of Anesthesiology and Pain Medicine, School of Medicine, Catholic University, Daegu, Korea

Abstract

Objectives: A vertebral compression fracture (VCF) is characterized by back pain and fracture of a vertebral body on spinal radiography. VCFs of the thoraco lumbar spine are common in the elderly, with approximately 1.5 million VCFs annually in the general US population [1, 2]. There is empirical evidence that acupuncture might benefit patients with a VCF. However, no randomized, controlled, clinical trials evaluating the efficacy and the safety of acupuncture for treating a VCF have been published. In Korea, acupuncture and herbal medication have been used to treat VCFs for many years. Therefore, we designed a randomized, controlled, pilot, clinical trial to obtain information for the design of a further full scale trial.

Methods: A five week protocol for a randomized, controlled, pilot, clinical trial is presented. Fourteen patients will be recruited and randomly allocated to two groups: a control group receiving interlaminar epidural steroid injections once a week for three weeks, and an experimental group receiving interlaminar epidural steroid injections plus acupuncture treatment (three acupuncture sessions per week for three weeks, nine sessions in total). The primary outcomes will be the pain intensity (visual analogue scale and PainVision™ system). The secondary outcome measurements will be the answers on the short form McGill pain questionnaire and the oswestry disability index. Assessments will be made at baseline and at one, three, and five weeks. The last assessment (week five) will take place two weeks after treatment cessation. This study will provide both an indication of feasibility and a clinical foundation for a future large scale trial. The outcomes will provide additional resources for incorporating acupuncture into existing treatments, such as nonsteroidal anti-inflammatory medications, narcotics and vertebral augmentation. This article describes the protocol.

1. Introduction

A vertebral compression fracture (VCF) is characterized by back pain and a fracture of a vertebral body on spinal radiography [1, 2]. VCFs of the thoraco lumbar spine are common in the elderly, with approximately 1.5 million VCFs annually in the general US population.
2. Materials and Methods

2.1. Study design

A protocol for a randomized, controlled, pilot, clinical trial is presented. This protocol adheres to the principles of the declaration of Helsinki and has been approved by the Institutional Review Board of Daegu Catholic University Hospital (IORB0004453), where the study will take place. The trial is registered with the U.S. National Institutes of Health Clinical Trials Registry (NCT01913587). Written consent will be obtained from each participant before any treatment is given.

The outcome assessments and statistical analyses will be performed by professionals blinded to the assignment of patients. The trial protocol is presented in Fig. 1. The trial will run for five weeks. Patients will be randomly allocated to two groups: a control group, in which patients will receive three interlaminar epidural steroid injections for three weeks, and an experimental group, in which patients will receive the same interlaminar epidural steroid injections as well as nine acupuncture sessions (three sessions per week for three weeks). Assessments will be made at baseline, and again at one, three, and five weeks. The last assessment (week five) will take place two weeks after treatment cessation.

2.2. Recruitment

Participants will be recruited through advertisements on hospital websites and on bulletin boards. If patients are interested in participation, they will be invited to visit the hospital for a screening meeting. Their eligibility will be determined by an anesthesiologist through physical and radiological examinations. If eligible, they will be guided through the informed consent process. After written consent has been obtained, a study researcher will randomly allocate the participants to one of the two groups. Treatments will be scheduled after randomization.

2.3. Participants

This study is designed as a pilot study, and a 20% dropout rate is expected. A target of 14 patients with a VCF has been set. Each group will include seven patients. Inclusion criteria are as follows: a VCF caused by trauma or osteoporosis; a minimum 15% loss of vertebral height; diagnosis by X-ray, computed tomography (CT), or MRI; or a VAS score of 5 or more; age over 50; recruitment at 2 weeks or more from onset; follow-up possible during the clinical trial; voluntary written informed consent. Exclusion criteria are as follows: recruitment within 2 weeks of onset; pathological fracture due to malignancy (myeloma) or osteomyelitis; major retropropulsion of bony segments into the spinal canal; bone metabolic disease; significant renal or hepatic disease; hypersensitive reaction to acupuncture treatment; senile dementia, impaired cognitive function or other cerebral disease, and severe psychiatric or psychological disorders; alcohol/drug abuse; ineligibility as determined by an anesthesiologist; refusal to participate in the trial or to provide informed consent; any contraindication to corticosteroid injection (e.g., insulin dependent diabetes); inability to comprehend or express oneself in the Korean language.

2.4. Randomization

Patients will be randomized using a computerized ran-
dom number generator by an independent statistician blinded to patient assignment in accordance with the Consolidated Standards of Reporting Trials (CONSORT) statement. Block randomization will be performed once the participants are confirmed to be eligible, and their written informed consent has been obtained.

2.5. Interventions

Patients will be randomly divided into two treatment groups: a control group (interlaminar epidural steroid injection) and an experimental group (interlaminar epidural steroid injection plus acupuncture). The interlaminar epidural steroid injections will be administered once per week for three weeks (three times in total), and the acupuncture sessions will be performed three times per week for three weeks (nine times in total). If patients take both interlaminar epidural injection and acupuncture, acupuncture will be taken 30 minutes after finishing the interlaminar epidural injection.

2.5.1. Interlaminar epidural steroid injection

The lumbar interlaminar epidural injections will be administered by an anesthesiologist under fluoroscopy in a sterile procedure room in an outpatient pain management department. The lumbar interlaminar epidural space will be identified by using the loss of resistance technique and by using fluoroscopic visualization with confirmation by using iohexol contrast medium. The epidural needle will be entered at the level of the vertebral compression fracture or one space below the level of the compression fracture. After confirmation of needle placement, 10 mL of a solution containing 2 mL of 0.5% preservative free bupivacaine hydrochloride, 10 mg of non particulate dexamethasone, and normal saline will be administered by injection.

2.5.2. Acupuncture treatment

The following acupuncture points will be used: two back transporting acupoints (located on the superior and the inferior sides of the fractured vertebral body), BI40, BL60, GB34, and ST36 (bilateral). In total, 12 acupuncture points will be used.

---

**Figure 1** Flow chart of the pilot, randomized, controlled trial.
Sterile disposable acupuncture needles (0.25 mm × 40 mm in size; DongBang Acupuncture Inc., Korea) will be manually inserted into the acupoints. After needle insertion, the De Qi sensation will be induced by using manual stimulation, and four back transporting acupoints will be stimulated by using an electro acupuncture device (ES-160; Ito Co. Ltd., Japan). The needles will be inserted for 20 ± 5 minutes and then removed.

2.6. Data collection

The primary outcome measurements will be the VAS and PainVision™ system scores. The secondary outcome measurements will be the answers on the short form-McGill pain questionnaire (SF-MPQ) and the Oswestry disability index (ODI). Both the primary and the secondary outcomes will be measured at baseline and at one, three, and five weeks. The schedule of treatment and outcome assessments is presented in Table 1.

2.6.1. Primary outcome measurements

1) VAS: Pain intensity will be assessed using a 10 cm VAS scale of subjective pain assessment. Each patient will rate his or her pain on a scale of 0 — 10 (0, absence of pain; 10, the worst pain imaginable) [24, 25]. VAS measurements will be made at baseline and, at one, three, and five weeks.

2) PainVision™: PainVision™ is a system used for the quantitative analysis of the perception and sensation of pain; it has recently been introduced in the field of pain and anesthesiology [26]. The PainVision™ system consists of four devices: (1) the main PainVision™ system unit, (2) a personal computer connected to the PainVision™ system, (3) sensors, and (4) a printer. The specific protocol for using the system is as follows [27]: First, sensors that transmit an electric current will be attached to the right medial forearm. The current perception threshold that indicates the pain threshold of each subject will be measured three times, and the mean values will be used for analysis. Second, the pain compatible electrical current will be measured by gradually increasing the pulsed current applied to the right medial forearm. The pain due to the VCF and the VAS, visual analogue scale; SF-MPQ, short form-McGill pain questionnaire; ODI, oswestry disability index.

Sterilized disposable acupuncture needles (0.25 mm × 40 mm in size; DongBang Acupuncture Inc., Korea) will be manually inserted into the acupoints. After needle insertion, the De Qi sensation will be induced by using manual stimulation, and four back transporting acupoints will be stimulated by using an electro acupuncture device (ES-160; Ito Co. Ltd., Japan). The needles will be inserted for 20 ± 5 minutes and then removed.

### Table 1 Schedule of treatments and outcome measurements throughout the 5-week pilot randomized controlled trial

| Measurement and treatment | Baseline | Treatment period | Follow-up period |
|---------------------------|----------|-----------------|------------------|
|                           | 0 week   | 1 week          | 2 week           |
| VAS                       | ✓        | ✓               | ✓                |
| PainVision™               | ✓        | ✓               | ✓                |
| SF-MPQ                    | ✓        | ✓               | ✓                |
| ODI                       | ✓        | ✓               | ✓                |
| Interlaminar epidural     | –        | ✓               | ✓                |
| steroid injection         | –        | ✓               | ✓                |
| acupuncture               | –        | ✓               | ✓                |
|                           | –        | ✓               | ✓                |

Pain intensity = 100 × (pain compatible electrical current − current perception threshold) / current perception threshold.

2.6.2. Secondary outcome measurements

1) SF-MPQ: The SF-MPQ, a shorter version of the McGill pain questionnaire (MPQ), is a multidimensional measure of perceived pain in adults with chronic pain [28, 29]. The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) from the original MPQ. The descriptors are rated on an intensity scale (0, none; 1, mild; 2, moderate; or 3, severe). The SF-MPQ also includes the present pain intensity (PPI) scale. The PPI scale is a measure of the magnitude of pain experienced by an individual and a numeric verbal combination that indicates overall pain intensity and includes six levels (0, none; 1, mild; 2, discomforting; 3, distressing; 4, horrible; and 5, excruciating) [30]. Higher numbers indicate more severe pain. The SF-MPQ will be measured at baseline and at one, three, and five weeks.

2) ODI: The ODI is one of the most frequently used tools for measuring disability related to low back pain [31]. The ODI contains 10 questions about daily activities, including inventories of pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sexual life, social life, and traveling. Each question is rated on a scale from 0 to 5 points. The ODI scores range from 0 to 50. Higher scores indicate greater disability. The validated Korean version of the ODI [32] will be administered at baseline, and at one, three, and five weeks.

2.7. Safety

The safety of acupuncture will be determined by the red blood cell (RBC) count, hemoglobin level, platelet count, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), hematocrit (HCT), total white blood cell (WBC) count, erythrocyte sedimentation rate (ESR), aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), creatinine level, serum sodium level, serum potassium level, and serum chloride level. All patients will be evaluated at two time points: at the screening visit and after treatment cessation.
Any reported adverse events will be recorded throughout the study, and vital signs will be monitored at each visit. The patients will be requested to voluntarily report information about adverse events, and the researcher will confirm the occurrence of adverse events through methods such as a medical interview. The details of the adverse events, such as the date of occurrence, degree of the adverse event, causal relationship with the treatment, other treatments or medications that are suspected to have caused the adverse event, and the treatment of the adverse event, will be recorded.

2.8. Withdrawal and dropout
All patients will have the right to withdraw from the study at any time. Participation will be ended at any stage if the patient refuses to continue, withdraws his or her consent, or violates the inclusion or exclusion criteria or the trial protocol. The trial will be stopped if the principal investigator believes that an unacceptable risk of a serious adverse event exists.

2.9. Statistical analysis
The statistical significance level will be set at 5%, and the data will be processed with the last observation carried forward method for the intention to treat analysis. Statistical analysis in this study will be based on the Clinical Trial Statistics Guidelines (KFDA, 2000) and will be performed using IBM SPSS Win ver. 19.0 statistical software.

All demographic and clinical characteristics of the subjects (e.g., sex, age, and weight) will be processed based on descriptive analyses. Quantitative data will be presented as the average and standard deviation, the median value, and the range. Qualitative data will be presented as the frequency and the percentage. The study will identify the comparative equivalence of demographic variables and clinical characteristics between the experimental and the control groups.

In order to identify differences in VAS, PainVision™, SF-MPQ and ODI scores between the experimental and the control group based on time (baseline, weeks one, three, and five), a repeated measure two factor analysis will be performed to identify differences between groups, differences within each group based on time, and the effects of the interactions of the variables based on group. If the interaction between group and time is statistically significant, the point at which the pattern of results between the two groups changes will be checked. The Chi square test will be used to compare groups and the incidence frequency of adverse events related to acupuncture and interlaminar epidural steroid injection.

3. Discussion
Nonsurgical management is one of the preferred approaches for treating a VCF [33]. In general, appropriate analgesics should be prescribed to reduce pain and, thus, promote early mobilization [34]. In those who do not achieve acceptably rapid symptomatic relief with nonsurgical treatment, the judicious use of vertebral augmentation by vertebroplasty or kyphoplasty may provide more rapid pain relief. However, long-term outcomes have not been defined [7]. Traditional nonsteroidal anti-inflammatory medications are related to the risk of nausea, gastritis, ulcers, gastrointestinal bleeding, and renal insufficiency [35]. Narcotics have significant side effects, including reduced gastrointestinal motility, urinary retention, reduced respiratory drive and cognitive deficits related with loss of balance, increase in the number of falls and depression [36]. Vertebroplasty and kyphoplasty are invasive procedures that carry risks of symptomatic epidural cement leakage, causing nerve root injury (in 0.4% to 4% of patients) [37, 38], and symptomatic cement pulmonary embolism (in approximately 0.1% of patients) [38, 39].

More worrisome is the possibility that the procedures may increase the risk of a subsequent VCF by increasing the mechanical load on the vertebrae adjacent to those being treated [40]. Considering the high prevalence of VCFs in the general population and the side effect of the present treatment, a demand for a more effective and safe therapy exists.

Acupuncture, one of the most important parts of complementary and alternative medicine, has been used for thousand years. In Korea, many patients with a VCF are treated using traditional Korean medicine, including acupuncture. However, no study so far has investigated the efficacy and the safety of acupuncture for treating a VCF. A pilot, randomized, controlled trial will provide the feasibility and a clinical foundation for a future full scale trial. The outcomes will provide additional resources for incorporating acupuncture into existing treatments such as nonsteroidal anti-inflammatory medications, narcotics, and vertebral augmentation.

Acknowledgment
This study was supported by a grant from the Ministry of Health & Welfare, Korea, 2013.

Conflict of interest
The authors declare that there are no conflict of interest.

References
1. Ensrud KE, Schousboe JT. Clinical practice. vertebral fractures. N Engl J Med. 2011;364(17):1634-42.
2. Cooper C, Atkinson EJ, O’Fallon WM, Melton LJ 3rd. Incidence of clinically diagnosed vertebral fractures: a population-based study in rochester, minnesota, 1985-1989. J Bone Miner Res. 1992;7(2):221-7.
3. Barr JD, Barr MS, Lemley TJ, McCann RM. Percutaneous vertebroplasty for pain relief and spinal stabilization. Spine. 2000;25(8):923-8.
4. Gertzbein SD, Khoury D, Bullington A, St John TA, Larson AI. Thoracic and lumbar fractures associated with skiing and snowboarding injuries according to the AO comprehensive classification. Am J Sports Med. 2012;40(8):1750-4.
5. Robinson Y, Heyde CE, Forsth P, Olerud C. Kyphoplasty in osteoporotic vertebral compression fractures-guidelines and technical considerations. J Orthop Surg Res. 2011;6(43):1-8.
6. Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med. 1998;128(10):793-800.
7. Kim DH, Vaccaro AR. Osteoporotic compression fractures of the spine; current options and considerations for treatment. Spine J. 2006;6(5):479-87.
8. Prather H, Hunt D, Watson JO, Gilula LA. Conservative care for patients with osteoporotic vertebral compression fractures. Phys Med Rehabil Clin N Am. 2007;18(3):577-91.
9. Lad SP, Patil CG, Lad EM, Boakye M. Trends in pathological vertebral fractures in the united states: 1993 to 2004. J Neurosurg Spine. 2007;7(3):305-10.
10. O'Neill TW, Silman AJ. Definition and diagnosis of vertebral fracture. J Rheumatol. 1997;24(6):1208-11.
11. Eastell R, Cedel SL, Wahner HW, Riggs BL, Melton LJ. Classification of vertebral fractures. J Bone Miner Res. 1991;6(3):207-15.
12. Longo UG, Loppini M, Denaro L, Maffulli N, Denaro V. Osteoporotic vertebral fractures: current concepts of conservative care. Br Med Bull. 2012;102:171-89.
13. Lucas TS, Einhorn TA. Osteoporosis: The role of the orthopaedist. J Am Acad Orthop Surg. 1993;1(1):48-56.
14. Prather H, Watson JO, Gilula LA. Nonoperative management of osteoporotic vertebral compression fractures. Injury. 2007;38(S3):40-8.
15. Kim DJ, Yun YH, Wang JM. Nerve-root injections for the relief of pain in patients with osteoporotic vertebral fractures. J Bone Joint Surg Br. 2003;85:250-3.
16. Bostrom MP, Lane JM. Future directions. augmentation of osteoporotic vertebral bodies. Spine. 1997;22(S24):38-42.
17. Truumees E, Hillbrand A, Vaccaro AR. Percutaneous vertebral augmentation. Spine J. 2004;4(2):218-29.
18. Vaccaro AR, Kim DH, Brodke DS, Harris M, Chapman J, Schildhauer T, et al. Diagnosis and management of thoracolumbar spine fractures. J Bone Joint Surg Am. 2003;85(12):2456-70.
19. Carlsson GP, Sjolund BH. Acupuncture for chronic low back pain: a randomized placebo-controlled study with long-term follow-up. Clin J Pain. 2001;17(4):296-305.
20. Sawazaki K, Mukaino Y, Kinoshita F, Honda T, Mohara O, Sakuraba H, et al. Acupuncture can reduce perceived pain, mood disturbances and medical expenses related to low back pain among factory employees. Ind Health. 2008;46(4):336-40.
21. Leibing E, Leonhardt U, Koster G, Goerlitz A, Rosenfeldt JA, Hilgers R, et al. Acupuncture treatment of chronic low-back pain - a randomized, blinded, placebo-controlled trial with 9-month follow-up. Pain. 2002;96(1-2):189-96.
22. Haake M, Muller IH, Schade-Brittinger C, Basler HD, Schafer H, Maier C, et al. German acupuncture trials (GERAC) for chronic low back pain: randomized, multicenter, blinded, parallel-group trial with 3 groups. Arch Intern Med. 2007;167(17):1892-8.
23. Brinkhaus B, Witt CM, Jena S, Linde K, Streng A, Wagenpfel S, et al. Acupuncture in patients with chronic low back pain: a randomized controlled trial. Arch Intern Med. 2006;166(4):450-7.
24. Revill SJ, Robinson JO, Rosen M, Hogg MI. The reliability of a linear analogue for evaluating pain. Anaesthesia. 1976;31(9):1191-8.
25. Carlsson AM. Assessment of chronic pain. I. aspects of the reliability and validity of the visual analogue scale. Pain. 1983;16(1):87-101.
26. Ikeno S, Kawamata M. Painvision. Masui. 2009;58(11):1367-72.
27. Matsumura H, Imai R, Gondo M, Watanabe K. Evaluation of pain intensity measurement during the removal of wound dressing material using 'the painvision system' for quantitative analysis of perception and pain sensation in healthy subjects. Int Wound J. 2012;9(4):451-5.
28. Burckhardt CS. The use of the mcgill pain questionnaire in assessing arthritis pain. Pain. 1984;19(3):305-14.
29. Melzack R. The short-form mcgill pain questionnaire. Pain. 1987;30:191-7.
30. Melzack R. The mcgill pain questionnaire: major properties and scoring methods. Pain. 1975;1(3):277-99.
31. Roland M, Morris R. A study of the natural history of back pain. part I: development of a reliable and sensitive measure of disability in low-back pain. Spine. 1983;8(2):141-4.
32. Jeon CH, Kim DJ, Kim SK, Kim DJ, Lee HM, Park HJ. Validation in the cross-cultural adaptation of the Korean version of the oswestry disability index. J Korean Med Sci. 2006;21(6):1092-7.
33. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001;285(3):320-3.
34. Alexandru D, So W. Evaluation and management of vertebral compression fractures. Perm J. 2012;16(4):46-51.
35. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343(21):1520-8.
36. Cherasse A, Muller G, Ornetti P, Piroth C, Tavernier C, Maillefert JF. Tolerance of opioids in patients with acute pain due to nonmalignant musculoskeletal disease. a hospital-based observational study. Joint Bone Spine. 2004;71(6):572-6.
37. Laredo JD, Hamze B. Complications of percutaneous vertebroplasty and their prevention. Skeletal Radiol. 2004;33(9):493-505.
38. Taylor RS, Fritzell P, Taylor RJ. Balloon kyphoplasty in the management of vertebral compression fractures: an updated systematic review and meta-analysis. Eur Spine J. 2007;16(8):1085-100.
39. Krueger A, Bliemel C, Zeitl R, Ruchholtz S. Management of pulmonary cement embolism after percutaneous vertebroplasty and kyphoplasty: a systematic review of the literature. Eur Spine J. 2009;18(9):1257-65.
Ji, et al. Vertebroplasty and kyphoplasty are associated with an increased risk of secondary vertebral compression fractures: a population-based cohort study. Osteoporos Int. 2009;20(5):819-26.